Position in GRFS
as of Jun 30, 2026
· filed Aug 13, 2026
Position Value
$3,391
+$1,659 QoQ
Shares Held
479
+121.8% QoQ
Ownership
0.000%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
#137
of 164 holders
Holding Since
Jun 2020
9 quarters on record
Voting authority
Sole 0%
Shared 0%
None 100%
Common Shares in GRFS Over Time
Shares Held
Position Value (USD)
Position in Drug Manufacturers - General
Healthcare · as of Jun 30, 2026Steward Partners Investment Advisory, LLC holds $502,917,200 across 18 Drug Manufacturers - General names. GRFS ranks #16 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | LLY |
ELI LILLY & Co
|
116,568 | $139,815,167 | |
| 2 | ABBV |
AbbVie Inc.
|
475,389 | $119,626,887 | |
| 3 | JNJ |
Johnson & Johnson
|
461,457 | $117,196,234 | |
| 4 | MRK |
Merck & Co., Inc.
|
318,918 | $40,980,963 | |
| 5 | AMGN |
Amgen Inc
|
79,642 | $28,839,961 | |
| 6 | BMY |
Bristol Myers Squibb Co
|
277,131 | $15,968,288 | |
| 7 | PFE |
Pfizer Inc
|
520,623 | $12,536,601 | |
| 8 | GILD |
Gilead Sciences, Inc.
|
66,698 | $8,426,625 |
All Filings in GRFS
Export CSV
9 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $3,391 | 479 | Shares | Sole | 2026-08-13 | |
| 2026-03-31 | $1,732 | 216 | Shares | Sole | 2026-05-08 | |
| 2025-12-31 | $2,019 | 216 | Shares | Sole | 2026-02-12 | |
| 2025-09-30 | $2,091 | 210 | Shares | Sole | 2025-11-12 | |
| 2025-06-30 | $1,898 | 210 | Shares | Sole | 2025-08-12 | |
| 2025-03-31 | $1,493 | 210 | Shares | Sole | 2025-05-13 | |
| 2024-12-31 | $691 | 93 | Shares | Sole | 2025-02-06 | |
| 2024-09-30 | $825 | 93 | Shares | Sole | 2024-11-14 | |
| 2020-06-30 | $893 | 49 | Shares | Sole | 2020-08-06 | |
| No filing history on record for this holder in this stock. | ||||||